Oxazolone and diclofenac-induced popliteal lymph node assay reactions are attenuated in mice orally pretreated with the respective compound: Potential role for the induction of regulatory mechanisms following enteric administration

Toxicology and Applied Pharmacology

Volumn 189, Issue 2, 2003, Pages 120-133

  Gutting, Bradford W ^a   Bouzahzah, Farida ^a   Kong, Philip L ^a   Updyke, Lawrence W ^b   Amacher, David E ^b   Craft, Joe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diclofenac; DNCB; Drug allergy; Drug hypersensitivity; Oral tolerance; Oxazolone; Popliteal lymph node assay (PLNA); Regulatory cell, CD8+; Systemic hypersensitivity

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CD4 ANTIGEN; CD8 ANTIGEN; DICLOFENAC; HAPTEN; IMMUNOSTIMULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLIVE OIL; OXAZOLONE;

ADOPTIVE TRANSFER; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; B LYMPHOCYTE; CELL ACTIVITY; CELL ISOLATION; CONTACT SENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERANCE; FEEDING; FOOT PAD; IMMUNOSTIMULATION; INJECTION; LYMPH NODE; LYMPH NODE CELL; MOUSE; NONHUMAN; POPLITEAL LYMPH NODE ASSAY; REGULATORY MECHANISM; SPLEEN CELL; T LYMPHOCYTE;

MURINAE;

EID: 0038441456     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-008X(03)00091-7     Document Type: Article

References (50)

1. Adkinson N.F., Essayan D., Gruchalla R., Haggerty H., Kawabata T., Sandler J.D., Updyke L., Shear N.H., Wierda D. Task force report future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions . J. Allergy Clin. Immunol. 109:2002;S461-S478.
2. Albers R., Broeders A., van der Pijl A., Seinen W., Pieters R. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol. Appl. Pharmacol. 143:1997;102-109.
3. Asherson G.L., Perera M.A.C.C., Thomas W.R. Contact sensitivity and the DNA response in mice to high and low doses of oxazolone low dose unresponsiveness following painting and feeding and its prevention by pretreatment with cyclophosphamide . Immunology. 36:1979;449-459.
4. Asherson G.L., Zembala M., Perera M.A.C.C., Mayhew B., Thomas W.R. Production of immunity and unresponsiveness in the mouse by feeding contact sensitizing agents and the role of suppressor cells in the Peyer's patches, mesenteric lymph nodes and other lymphoid tissue. Cell. Immunol. 33:1977;145-155.
5. Barbaud A., Trechot P., Aublet-Cuvelier A., Feichert-Penetrat S., Schmutz J.L. Bufexamac and diclofenac frequency of contact sensitization in the absence of cross-reactivity . Contact Dermatitis. 39:1998;272-273.
6. Bloksma N., Kubicka-Muranyi M., Schuppe H.-C., Gleichmann E., Gleichmann H. Predictive immunological test systems suitability of the popliteal lymph node assay in mice and rats . Crit. Rev. Toxicol. 25:1995;369-396.
7. Boelsterli U.A., Zimmerman H.J., Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs molecular mechanisms and pathology . Crit. Rev. Toxicol. 25:1995;207-235.
8. Borda I.T., Slone D., Jick H. Assessment of adverse reactions within a drug surveillance program. JAMA. 205:1968;645-647.
9. Chen Y., Inobe J., Weiner H.L. Induction of oral tolerance to myelin basic protein in Cd8-depleted mice both CD4+ and CD8+ cells mediate active suppression . J. Immunol. 155:1995;910-916.
10. Craig T.J., Mende C. Common allergic and allergic-like reactions to medications when the cure becomes the curse . Drug Allergies. 105:1999;173-181.
11. Dearman R.J., Basketter D.A., Kimber I. Characterization of chemical allergens as a function of divergent cytokine secretion profiles induced in mice. Toxicol. Appl. Pharmacol. 138:1996;308-316.
12. Dearman R.J., Ramdin L.S., Basketter D.A., Kimber I. Inducible interleukin-4-secreting cells provoked in mice during chemical sensitization. Immunology. 81:1994;551-557.
13. De Bakker J.M., Kammuller M.E., Muller E.S., Lam A.W., Seinen W., Bloksma N. Kinetics and morphology of chemically induced popliteal lymph node reactions compared with antigen-, mitogen-, and graft-versus-host-reaction-induced responses. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. 58:1990;279-287.
14. Descotes J., Verdier F. Popliteal lymph node assay. Methods Immunotoxicol. 1:1995;189-196.
15. deShazo R.D., Kemp S.F. Allergic reactions to drugs and biological agents. JAMA. 278:1997;1895-1906.
16. Desvignes C., Bour H., Nicolas J.-F., Kaiserlian D. Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility complex class-II deficient mice and in CD4+ T cell-depleted mice. Eur. J. Immunol. 26:1996;1756-1761.
17. + T cells . J. Immunol. 164:2000;2515-2522.
18. DeSwarte R.D. Drug allergy. Patterson R., Gammer L.C., Greenberger P.A., Zeiss C.R. Allergic Diseases Diagnosis and Management . 4th ed. 1993;395-551 Lippencott, Philadelphia.
19. Galliaerde V., Desvignes C., Peyron E., Kaiserlian D. Oral tolerance to haptens intestinal epithelial cells from 2,4-dinitrochlorobenzene-fed mice inhibit hapten-specific T cell activation in vitro . Eur. J. Immunol. 25:1995;1385-1390.
20. Gautam S.C., Battisto J.R. Suppression on contact sensitivity and cell-mediated lympholysis by oral administration of hapten is caused by different mechanisms. Cell. Immunol. 78:1983;295-304.
21. Gautam S.C., Battisto J.R. Orally induced tolerance generates an efferently acting suppressor T cell and an acceptor T cell that together down-regulate contact sensitivity. J. Immunol. 135:1985;2975-2983.
22. Gautam S.C., Beckman K.D., Wong H.L., Battisto J.R. Two distinct suppressor T cells acting in concert cause suppression of cytotoxic T lymphocyte (CTL) responses to hapten-altered self in vivo. J. Immunol. 130:1983;2557-2560.
23. Gautam S.C., Battisto J.R. Feeding trinitrochlorobenzene inhibits development of hapten-specific cytotoxic T lymphocytes by interfering with helper T-cell function. Reg. Immunol. 2:1989;33-41.
24. Gautam S.C., Chikkala N.F., Battisto J.R. Oral administration of the contact sensitizer trinitrochlorobenzene initial sensitization and subsequent appearance of a suppressor population . Cell. Immunol. 125:1990;437-448.
25. Gebhardt M., Reuter A., Knoft B. Allergic contact dermatitis from topical diclofenac. Contact Dermatitis. 30:1994;183-184.
26. Gleichmann H. Studies on the mechanism of drug sensitization T-cell-dependent popliteal lymph node reaction to diphenylhydantoin . Clin. Immunol. Immunopathol. 18:1981;203-211.
27. Goebel C., Griem P., Sachs B., Bloksma N., Gleichmann E. The popliteal lymph node assay in mice screening of drugs and other chemicals for immunotoxic hazard . Inflamm. Res. 45:1996;S85-S90.
28. Griem P., Wulferink M., Sachs B., Gonzalez J.B., Gleichmann E. Allergic and autoimmune reactions to xenobiotics how do they arise? Immunol. Today. 19:1998;133-141.
29. Gutting B.W., Schomaker S.J., Kaplan A.K., Amacher D.E. A comparison of the direct and reporter antigen popliteal lymph node assay for the detection of immunomodulation by low molecular weight compounds. J. Toxicol. Sci. 51:1999;71-79.
30. Gutting B.W., Updyke L.W., Amacher D.E. Diclofeanc activates T cells in the direct popliteal lymph node assay and selectively induces IgG1 and IgE against co-injected TNP-OVA. Toxicol. Lett. 131:2002;167-180.
31. Gutting B.W., Updyke L.W., Amacher D.E. BALB/c mice orally pretreated with diclofenac have augmented and accelerated PLNA responses to diclofenac. Toxicology. 172:2002;217-230.
32. Hastings K.L. Pre-clinical methods for detecting the hypersensitivity potential of pharmaceuticals regulatory considerations . Toxicology. 158:2001;85-89.
33. Ke Y., Kapp J.A. Oral antigen inhibits priming of CD8+ CTL, CD4+T cells, and antibody responses while activating CD8+ suppressor T cells. J. Immunol. 156:1996;916-921.
34. Kimber I. The local lymph node assay and potential application to the identification of drug allergens. Toxicology. 158:2001;59-64.
35. Lebrec H., Kerdine S., Gaspard I., Pallardy M. Th(1)/Th(2) responses to drugs. Toxicology. 158:2001;25-29.
36. Lowney E.D. Suppression of contact sensitization in man by prior feeding of antigen. J. Invest. Dermatol. 61:1973;90-95.
37. Lowney E.D. A single step procedure for inducing partial tolerance of DNCB in human subjects. J. Invest. Dermatol. 63:1974;260-261.
38. Manetz T.S., Meade B.J. Development of a flow cytometry assay for the identification and differentiation of chemicals with the potential to elicit irritation, IgE-mediated, or T cell-mediated hypersensitivity responses. Toxicol. Sci. 48:1999;206-217.
39. Park B.K., Pirmohamed M., Kitteringham N.R. Role of drug disposition in drug hypersensitivity a chemical, molecular, and clinical perspective . Chem. Res.Toxicol. 11:1998;969-988.
40. Pichler W.J. Predictive drug allergy testing an alternative view point . Toxicology. 158:2001;31-41.
41. Pieters R. The popliteal lymph node assay a tool for predicting drug allergies . Toxicology. 158:2001;65-69.
42. Pieters R., Albers R. Screening tests for autoimmune-related immunotoxicity. Environ. Health Perspect. 107:1999;673-677.
43. Salama A., Kroll H., Wittman G., Mueler-Eckhardt C. Diclofenac-induced immune haemolytic anaemia simultaneous occurrence of red blood cell autoantibodies and drug-dependent antibodies . Br. J. Haematol. 95:1996;640-644.
44. Skoutakis V.A., Carter C.A., Mickle T.R., Smith V.H., Arkin C.R., Allisandratos J., Petty D.E. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell. Clin. Pharm. 22:1988;850-859.
45. Song Y., Connor D.T., Doubleday R., Sorenson R.J., Sercel A.D., Unangst P.C., Roth B.D., Gilertsen R.B., Chan K., Schrier D.J., Guglietta A., Bornemeier D.A., Dyer R.D. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent,selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J. Med. Chem. 42:1999;1151-1160.
46. Ueda K., Higashi N., Kume A., Ikushima-Fujimoto M., Ogiwara S. Allergic contact dermatitis due to diclofenac and indomethacin. Contact Dermatitis. 39:1998;323.
47. Valsecchi R., Pansera B., Leghissa P., Reseghetti A. Allergic contact dermatitis of the eyelids and conjuctivitis from diclofenac. Contact Dermatitis. 34:1996;150-151.
48. Van der Klauw M.M., Wilson J.H.P., Stricker B.H.C. Drug-associated anaphylaxis 20 years of reporting in The Netherlands (1974-1994) and review of the literature . Clin. Exp. Allergy. 26:1996;1355-1363.
49. Ware J.A., Graf M.L., Martin B.M., Lustburg L.R., Pohl L.R. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats possible role in allergic reactions . Chem. Res. Toxicol. 11:1998;164-171.
50. Zhou J., Carr R.I., Liwski R.S., Stadnyk A.W., Lee T.D.G. Oral exposure to alloantigen generates intragraft CD8+ regulatory cells. J. Immunol. 167:2001;107-113.